Retraction: Zerumbone abolishes RANKL-induced NF-KB activation, inhibits osteoclastogenesis, and suppresses human breast cancer–induced bone loss in athymic nude mice (Cancer Research (2009) 69 (1477–1484) DOI: 10.1158/0008-5472.CAN-08-3249);Zerumbone abolishes RaNKL-induced NF-κB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1477-1484

  Sung, Bokyung ^a   Murakami, Akira ^b   Oyajobi, Babatunde O ^c   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SESQUITERPENE DERIVATIVE; UNCLASSIFIED DRUG; ZERUMBONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

EID: 60549113238     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-1827     Document Type: Erratum

References (49)

1. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49.
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
3. Aggarwal BB. Signalling pathways of the TNF super-family: a double-edged sword. Nat Rev Immunol 2003;3: 745-56.
4. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-7.
5. Romas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161: 1419-27.
6. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397: 315-23.
7. Simonet WS, Lacey DL, Dunstan CR, et al. Osteopro-tegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
8. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
9. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev ancer 2002;2: 584-93.
10. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31.
11. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998;160:403-9.
12. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 2002;29:11-6.
13. Tanaka T, Shimizu M, Kohno H, et al. Chemo-prevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet. Life Sci 2001;69:1935-45.
14. Murakami A, Hayashi R, Tanaka T, Kwon KH, Ohigashi H, Safitri R. Suppression of dextran sodium sulfate-induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination. Biochem Pharmacol 2003; 66:1253-61.
15. Murakami A, Tanaka T, Lee JY, et al. Zerumbone, a sesquiterpene in subtropical ginger, suppresses skin tumor initiation and promotion stages in ICR mice. Int J Cancer 2004;110:481-90.
16. Huang GC, Chien TY, Chen LG, Wang CC. Antitumor effects of zerumbone from Zingiber zerumbet in P-388D1 cells in vitro and in vivo. Planta Med 2005;71:219-24.
17. Szabolcs A, Tiszlavicz L, Kaszaki J, et al. Zerumbone exerts a beneficial effect on inflammatory parameters of cholecystokinin octapeptide-induced experimental pancreatitis but fails to improve histology. Pancreas 2007;35: 249-55.
18. Takada Y, Murakami A, Aggarwal BB. Zerumbone abolishes NF-κB and IκBa kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene 2005;24:6957-69.
19. Murakami A, Takahashi M, Jiwajinda S, Koshimizu K, Ohigashi H. Identification of zerumbone in Zingiber zerumbet Smith as a potent inhibitor of 12-O-tetrade-canoylphorbol-13-acetate-induced Epstein-Barr virus activation. Biosci Biotechnol Biochem 1999;63:1811-2.
20. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96: 3540-5.
21. Wei S, Teitelbaum SL, Wang MW, Ross FP. Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors. Endocrinology 2001; 142:1290-5.
22. Sung B, Pandey MK, Aggarwal BB. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-κB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting proteinregulated IκBa kinase activation. Mol Pharmacol 2007; 71:1703-14.
23. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001;61:2572-8.
24. Kobayashi Y, Mizoguchi T, Take I, Kurihara S, Udagawa N, Takahashi N. Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem 2005;280:11395-403.
25. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109 Suppl:S81-96.
26. Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267:632-7.
27. Lai FP, Cole-Sinclair M, Cheng WJ, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004; 126:192-201.
28. Park BK, Zhang H, Zeng Q, et al. NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13:62-9.
29. Uhlik M, Good L, Xiao G, et al. NF-κB-inducing kinase and IκB kinase participate in human T-cell leukemia virus I Tax-mediated NF-κB activation. J Biol Chem 1998;273:21132-6.
30. Novack DV, Yin L, Hagen-Stapleton A, et al. The IκB function of NF-κB2 p100 controls stimulated osteoclas-togenesis. J Exp Med 2003;198:771-81.
31. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004;279:37219-22.
32. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
33. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-β via NF-κB that restrains osteoclastogenesis and bone resorption. J Biol Chem 2006;281:15809-20.
34. Franzoso G, Carlson L, Xing L, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997;11:3482-96.
35. Abu-Amer Y, Dowdy SF, Ross FP, Clohisy JC, Teitelbaum SL. TAT fusion proteins containing tyrosine 42-deleted IκBa arrest osteoclastogenesis. J Biol Chem 2001;276:30499-503.
36. Clohisy JC, Roy BC, Biondo C, et al. Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J Immunol 2003;171:5547-53.
37. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88: 2989-94.
38. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
39. Bhatia P, Sanders MM, Hansen MF. Expression of receptor activator of nuclear factor-κB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 2005;11:162-5.
40. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175-84.
41. Biswas DK, Shi Q, Baily S, et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42.
42. Lipton A. Biochemical bone markers in breast cancer. Cancer Treat Rev 2006;32 Suppl 1:20-2.
43. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 2008; 139:23-30.
44. Mariotti A. Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 2008;72:919-29.
45. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36.
46. Gevorgyan A, Enepekides DJ. Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare. Curr Opin Otolaryngol Head Neck Surg 2008;16:325-30.
47. Body JJ, Facon T, Coleman RE, et al. Astudy of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8.
48. Hunt NC, Fujikawa Y, Sabokbar A, Itonaga I, Harris A, Athanasou NA. Cellular mechanisms of bone resorption in breast carcinoma. Br J Cancer 2001;85:78-84.
49. Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 2005;116:253-62.